Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in
drug-delivery platforms, announced that final study results of a 2018 clinical
study evaluating the use of its proprietary drug-delivery system have been
published (http://ibn.fm/AYzRL)
(http://ibn.fm/PfnAA).
Published in Advances in Therapy, a peer-reviewed medical journal,
the human clinical study evaluated CBD delivery and effectiveness using
LXRP-patented, DehydraTECH(TM)-powered TurboCBD(TM) capsules.
Key findings highlighted in the publication included the
following:
- CBD
in-plasma levels with the TurboCBD 90 mg dose were significantly higher
than with the generic 90 mg dose at both 90 and 120 minutes (p < 0.05);
- Only
the TurboCBD 90 mg dose was elevated (i.e., greater than placebo) at 30
minutes (p < 0.05) and remained elevated (i.e., greater than placebo)
at 4 hours (p < 0.01);
- Mean
arterial blood pressure (MAP) in a subgroup analysis was significantly
decreased with only the TurboCBD 90 mg dose relative to baseline (p <
0.05); and
- Cerebral
perfusion analyzed by an index of conductance in the middle cerebral
artery (MCA) in this subgroup was significantly higher with only the
TurboCBD 90 mg dose relative to baseline (p < 0.001).
The key study was conducted and well tolerated in a dozen
healthy young male athletes, with researchers concluded that additional studies
were called for. Specifically, the report notes that “further acute and chronic
dosing investigations in older and cerebrovascular-compromised patients may
shed light on the vascular and clinical impacts of increased CBD
bioavailability.”
Already the owner of more than 60 patent applications
worldwide, Lexaria was recently granted two patents for “treating certain
conditions including but not limited to heart disease, neurological diseases
such as Alzheimer’s, Parkinson’s, schizophrenia” and others. The key findings
from this most recent study may prove timely, considering the demonstrated
effectiveness of DehydraTECH technology in increasing cerebral blood flow and
perhaps providing increased efficiency at delivering certain drugs to the
brain.
In its report, Advances in Therapy also
referenced a second study published recently by a separate group of researchers
that evaluated a comparable CBD dose with bioabsorption findings representative
of the cannabinoid edibles industry sector in general. The results indicate
that the rate of bioabsorption of the CBD from the competitive 100 mg
formulation was virtually nondetectable within 30 minutes of administration,
whereas the TurboCBD 90 mg dose delivered as much drug at 30 minutes as the
competitor formulation required nearly 2.5 hours to achieve.
Lexaria’s DehydraTECH drug-delivery technology improves the
way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time
of onset; and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in
the cannabis industry for use in cannabinoid beverages, edibles and oral
products, as well as to a world-leading tobacco producer for the development of
smokeless, oral-based nicotine products. Lexaria operates a licensed in-house
research laboratory and holds a robust intellectual property portfolio with 16
patents granted and more than 60 patents pending worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
